Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Chief Financial Officer | August 07, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 14,815 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Gift · Disposed 750 · Balance 14,815 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 11, 2026 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GiftCommon Shares | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-345111 · ownership.xml · nonDerivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,815 Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-253925 · ownership.xml · derivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Shares · 19,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: This restricted stock unit award was granted on May 29, 2026 with respect to 19,500 Common Shares, with 100% of the shares vesting on November 29, 2028. F2 · derivative.expiration_date: This restricted stock unit award was granted on May 29, 2026 with respect to 19,500 Common Shares, with 100% of the shares vesting on November 29, 2028. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,708 | $46.78 | $173,460.24 |
DisclosureSEC source: 0001193125-26-122268 · ownership.xml · nonDerivative · entry 2 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,565 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-122268 · ownership.xml · derivative · entry 5 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Shares · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F6 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. F6 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-122268 · ownership.xml · derivative · entry 4 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Shares · 27,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2026 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2026 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 38,499 | $0.00 Strike: $46.24 | $0.00 |
DisclosureSEC source: 0001193125-26-122268 · ownership.xml · derivative · entry 3 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,499 Underlying: Common Shares · 38,499 shares Expires 2036-03-20 F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F4 · derivative.exercise_date: This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-122268 · ownership.xml · nonDerivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GiftCommon Shares | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111284 · ownership.xml · nonDerivative · entry 5 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,023 F4 · kind: Reporting person remains subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. Transfers of lock-up securities as a bona fide gift are permitted. No consideration was received by the reporting person in connection with such transfer. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,021 | $48.26 | $194,053.46 |
DisclosureSEC source: 0001193125-26-111284 · ownership.xml · nonDerivative · entry 4 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,773 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,848 | $48.26 | $282,224.48 |
DisclosureSEC source: 0001193125-26-111284 · ownership.xml · nonDerivative · entry 3 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,794 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 6,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111284 · ownership.xml · derivative · entry 7 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Shares · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F6 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. F6 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111284 · ownership.xml · derivative · entry 6 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 6,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111284 · ownership.xml · nonDerivative · entry 2 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111284 · ownership.xml · nonDerivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 34,972 | $0.00 Strike: $45.15 | $0.00 |
DisclosureSEC source: 0001193125-26-022845 · ownership.xml · derivative · entry 3 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,667 Underlying: Common Shares · 34,972 shares Expires 2033-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 34,972 | $60.19 | $2,104,964.68 |
DisclosureSEC source: 0001193125-26-022845 · ownership.xml · nonDerivative · entry 2 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,767 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 34,972 | $45.15 | $1,578,985.80 |
DisclosureSEC source: 0001193125-26-022845 · ownership.xml · nonDerivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,339 | $0.00 Strike: $44.31 | $0.00 |
DisclosureSEC source: 0001193125-26-007875 · ownership.xml · derivative · entry 7 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,493 Underlying: Common Shares · 6,339 shares Expires 2033-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on October 13, 2023 with respect to 13,832 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,361 | $0.00 Strike: $45.15 | $0.00 |
DisclosureSEC source: 0001193125-26-007875 · ownership.xml · derivative · entry 6 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,639 Underlying: Common Shares · 23,361 shares Expires 2033-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,763 | $60.21 | $347,009.82 |
DisclosureSEC source: 0001193125-26-007875 · ownership.xml · nonDerivative · entry 5 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,767 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.4800, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,004 | $60.00 | $300,240.00 |
DisclosureSEC source: 0001193125-26-007875 · ownership.xml · nonDerivative · entry 4 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,530 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 18,933 | $60.18 | $1,139,386.05 |
DisclosureSEC source: 0001193125-26-007875 · ownership.xml · nonDerivative · entry 3 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,534 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.0000 to $60.7300, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 6,339 | $44.31 | $280,881.09 |
DisclosureSEC source: 0001193125-26-007875 · ownership.xml · nonDerivative · entry 2 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 23,361 | $45.15 | $1,054,749.15 |
DisclosureSEC source: 0001193125-26-007875 · ownership.xml · nonDerivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 22:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,000 | $56.89 | $56,885.80 |
DisclosureSEC source: 0001193125-25-331162 · ownership.xml · nonDerivative · entry 3 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,767 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.8200 to $56.9900, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 22:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,472 | $56.33 | $308,262.38 |
DisclosureSEC source: 0001193125-25-331162 · ownership.xml · nonDerivative · entry 2 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,767 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.7800 to $56.7700, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 22:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,528 | $55.10 | $194,400.56 |
DisclosureSEC source: 0001193125-25-331162 · ownership.xml · nonDerivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,239 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.7100 to $55.7050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 21:36 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $67.74 | $0.00 |
DisclosureSEC source: 0001193125-25-230505 · ownership.xml · derivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Shares · 16,500 shares Expires 2035-10-03 F1 · derivative.exercise_date: This option was granted on October 3, 2025 with respect to 16,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 3, 2025. Read SEC document |
| May 30, 2025 Filed Jun 4, 2025 01:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-081362 · ownership.xml · derivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: This restricted stock unit award was granted on May 30, 2025 with respect to 20,000 Common Shares, with 100% of the shares vesting on May 30, 2028. F2 · derivative.expiration_date: This restricted stock unit award was granted on May 30, 2025 with respect to 20,000 Common Shares, with 100% of the shares vesting on May 30, 2028. Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,197 | $41.23 | $90,582.31 |
DisclosureSEC source: 0000950170-25-043973 · ownership.xml · nonDerivative · entry 2 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,767 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-043973 · ownership.xml · derivative · entry 3 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Shares · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-043973 · ownership.xml · nonDerivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,762 | $41.80 | $157,251.60 |
DisclosureSEC source: 0000950170-25-041471 · ownership.xml · nonDerivative · entry 2 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,714 F2 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-041471 · ownership.xml · derivative · entry 5 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Shares · 27,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 36,666 | $0.00 Strike: $42.12 | $0.00 |
DisclosureSEC source: 0000950170-25-041471 · ownership.xml · derivative · entry 4 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,666 Underlying: Common Shares · 36,666 shares Expires 2035-03-14 F4 · derivative.exercise_date: This option was granted on March 14, 2025 with respect to 36,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-041471 · ownership.xml · derivative · entry 3 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-041471 · ownership.xml · nonDerivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-115693 · ownership.xml · derivative · entry 2 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on October 16, 2024 with respect to 15,000 Common Shares, with 100% of the shares vesting on October 16, 2027. F3 · derivative.expiration_date: This restricted stock unit award was granted on October 16, 2024 with respect to 15,000 Common Shares, with 100% of the shares vesting on October 16, 2027. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 21:35 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 18,333 | $0.00 Strike: $49.00 | $0.00 |
DisclosureSEC source: 0000950170-24-115693 · ownership.xml · derivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,333 Underlying: Common Shares · 18,333 shares Expires 2034-10-16 F1 · derivative.exercise_date: This option was granted on October 16, 2024 with respect to 18,333 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of on November 16, 2024. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-035516 · ownership.xml · derivative · entry 2 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 20, 2024 with respect to 25,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 36,168 | $0.00 Strike: $72.94 | $0.00 |
DisclosureSEC source: 0000950170-24-035516 · ownership.xml · derivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,168 Underlying: Common Shares · 36,168 shares Expires 2034-03-20 F1 · derivative.exercise_date: This option was granted on March 20, 2024 with respect to 36,168 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2024. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,524 | $72.69 | $256,159.56 |
DisclosureSEC source: 0000950170-24-032990 · ownership.xml · nonDerivative · entry 2 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,476 F2 · kind: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-032990 · ownership.xml · derivative · entry 3 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 21:45 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-032990 · ownership.xml · nonDerivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| October 13, 2023 Filed Oct 17, 2023 21:52 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,832 | $0.00 Strike: $44.31 | $0.00 |
DisclosureSEC source: 0000950170-23-053820 · ownership.xml · derivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,832 Underlying: Common Shares · 13,832 shares Expires 2033-10-13 F1 · derivative.exercise_date: This option was granted on October 13, 2023 with respect to 13,832 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 13, 2023. Read SEC document |
| March 14, 2023 Filed Mar 14, 2023 21:50 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $45.15 | $0.00 |
DisclosureSEC source: 0001209191-23-018571 · doc4.xml · derivative · entry 2 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2033-03-14 F3 · derivative.exercise_date: This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months. Read SEC document |
| March 14, 2023 Filed Mar 14, 2023 21:50 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018571 · doc4.xml · derivative · entry 1 Prasad Raju · CIK 0001968317 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027. F2 · derivative.expiration_date: This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.